ReviewCurrent infectious disease reports2018
Immune Monitoring for CMV in Transplantation.
Review in Current infectious disease reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 57 citations in OpenAlex.
- Immune Monitoring-Guided Versus Fixed Duration of Antiviral Prophylaxis Against Cytomegalovirus in Solid-Organ Transplant Recipients: A Multicenter, Randomized Clinical Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Trial
- Mechanisms and Determinants of CMV Reactivation in Kidney Transplantation.International journal of molecular sciences · 2026Review
- An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Pre-transplant IE1-specific T-cell response and CD8Frontiers in immunology · 2025Article
- Clinical manifestations and immune markers of non-HIV-related CMV retinitis.BMC infectious diseases · 2024Article
- Article
- Performance of a Global Functional Assay Based on Interferon-γ Release to Predict Infectious Complications and Cancer After Kidney Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Interferon-gamma FlowSpot assay for the measurement of the T-cell response to cytomegalovirus.Heliyon · 2023Article
- CMV-IgG pre-allogeneic hematopoietic stem cell transplantation and the risk for CMV reactivation and mortality.Bone marrow transplantation · 2023Article
- Torque teno virus viremia and QuantiFERONFrontiers in medicine · 2023Article
- Patient years lost due to cytomegalovirus serostatus mismatching in the scientific registry of transplant recipients.Frontiers in immunology · 2023Article
- Model to predict on-treatment restoration of functional HBV-specific CD8Alimentary pharmacology & therapeutics · 2022Article
- Laboratory diagnostic testing for cytomegalovirus infection in solid organ transplant patients.Korean journal of transplantation · 2022Review
- Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma.Current oncology (Toronto, Ont.) · 2022Article
- QuantiFERON-Cytomegalovirus Assay for Prediction of Cytomegalovirus Viremia in Kidney Transplant Recipients: Study From High Cytomegalovirus Seroprevalence Country.Frontiers in cellular and infection microbiology · 2022Article
- Viral infections in lung transplantation.Journal of thoracic disease · 2021Review
- In-depth summary over cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation recipients.Virusdisease · 2021Review
- Article
- Human cytomegalovirus infection: A considerable issue following allogeneic hematopoietic stem cell transplantation.Oncology letters · 2021Review
- Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation.Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewImmune monitoring to determine when and how the recovery of cytomegalovirus (CMV)-specific T-cells occurs post-transplantation may help clinicians to risk stratify individuals at risk of complications from CMV. We aimed to review all recent clinical studies using CMV immune monitoring in the pre- and post-transplant setting including the use of recently developed standardized assays (Quantiferon-CMV and the CMV ELISPOT) to better understand in whom, when, and how immune monitoring is best used. RECENT
findingsPre-transplant assessment of CMV immunity in solid-organ transplant recipients where CMV seropositive recipients had undetectable cell-mediated responses despite past immunity has shown that they are at a much higher risk of developing CMV reactivation. Post-transplant CMV immune monitoring can guide (shorten or prolong) the duration of antiviral prophylaxis, identify recipients at risk of post-prophylaxis CMV disease, and predict recurrent CMV reactivation. Thus, CMV immune monitoring, in addition to current clinical and DNA-based monitoring for CMV, has the potential to be incorporated into routine clinical care to better improve CMV management in both the stem and solid-organ transplant population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.